***News Stories Thread*** ONGOING 2019

Please feel free to read, share your thoughts, your stories and connect with others!
User avatar
Maggie Nell
Posts: 1122
Joined: Wed May 27, 2015 1:57 am
Location: Melbourne, Australia

Re: ***News Stories Thread*** ONGOING 2019

Postby Maggie Nell » Mon Jul 01, 2019 2:22 am

Society may not want to know about woundedness, or cancer, or mortality, but an increasing number of people are living beyond cancer treatment and being forced to confront precisely these things. Arthur Frank called ours a remission society:” a place where many of us have had cancer and may pass as healthy citizens, but are in fact only on visas.”

We require periodic checkups and know we could be expelled at any time. In such a context, it is even more urgent that those with cancer tell their stories.



“To use a metaphor at a time like this would be obscene”: a study of cancer, poetry and metaphor

This paper will examine the role of metaphor in relation to the scandal of cancer. It will consider the impact of metaphors drawn
from popular culture, biomedicine, alternative medicine, and the holistic health movement.
by Cathy Altmann
University of Melbourne

https://arts.monash.edu/__data/assets/p ... ltmann.pdf
DX April 2015, @ 54
35mm poorly diff. tumour, incidental finding following emergency r. hemicolectomy
for ileo-colic intussusception.
Lymph nodes: 0/22
T3 N0 MX
July 2019 : pending liver U/S, colonoscopy
rut roh

User avatar
CRguy
Posts: 9928
Joined: Sun Feb 10, 2008 6:00 pm

A Chemotherapy-Free Targeted Therapy Defines a New Standard of Care in Metastatic Colorectal Cancer

Postby CRguy » Fri Jul 12, 2019 3:53 pm

The regimen provided the first survival benefit of a chemotherapy-free therapy in prospective, biomarker-defined patients.

https://www.practiceupdate.com/content/ ... 544/55/1/2

Dr. Grothey concluded that triplet therapy using encorafenib + binimetinib + cetuximab and doublet therapy using encorafenib + cetuximab improved overall survival and objective response rates significantly vs the standard of care in patients with BRAFV600E-mutant, metastatic colorectal cancer.
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far

User avatar
CRguy
Posts: 9928
Joined: Sun Feb 10, 2008 6:00 pm

Maintenance With Panitumumab Alone vs Panitumumab + Fluorouracil–Leucovorin in Patients With RAS Wild-Type Metastatic Co

Postby CRguy » Fri Jul 12, 2019 3:55 pm

Maintenance With Panitumumab Alone vs Panitumumab + Fluorouracil–Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer

https://www.practiceupdate.com/journals ... rt-insight
TAKE-HOME MESSAGE
• The authors of this prospective, randomized phase II trial compared single-agent anti-EGFR (panitumumab) maintenance therapy with maintenance chemotherapy (fluorouracil and leucovorin) plus panitumumab following induction treatment with panitumumab and FOLFOX-4 in 229 patients with previously untreated RAS wild-type metastatic colorectal cancer. The 10-month progression-free survival was 49.0% with panitumumab and 59.9% with chemotherapy plus panitumumab (P=.01). The combination of fluorouracil, leucovorin, and panitumumab was associated with increased toxicity compared with panitumumab alone.
• Among patients with RAS wild-type metastatic colorectal cancer, progression-free survival was inferior with panitumumab monotherapy compared with panitumumab plus fluorouracil–leucovorin.
– Paul Hampel, MD
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far

User avatar
CRguy
Posts: 9928
Joined: Sun Feb 10, 2008 6:00 pm

Prognosis of Microsatellite Instability and/or Mismatch Repair Deficiency Stage III Colon Cancer Patients After Disease

Postby CRguy » Fri Jul 12, 2019 4:02 pm

Prognosis of Microsatellite Instability and/or Mismatch Repair Deficiency Stage III Colon Cancer Patients After Disease Recurrence Following Adjuvant Treatment

https://www.practiceupdate.com/c/86267/ ... rt-insight

TAKE-HOME MESSAGE
• This pooled analysis was designed to evaluate the prognostic significance of microsatellite instability/deficient mismatch repair (MSI/dMMR) status after disease recurrence among patients who received adjuvant treatment for stage III colon cancer. MSI/dMMR tumors were associated with significantly longer survival after recurrence compared with microsatellite stable/proficient MMR (MSS/pMMR) tumors, even in patients treated with only standard oxaliplatin-based adjuvant chemotherapy regimens. The presence of the BRAFV600E mutation was associated with a poor prognosis, irrespective of MSI status.
• The MSI/dMMR phenotype in patients with stage III colon cancer with recurrence was associated with improved survival outcomes compared with the MSS/pMMR phenotype. BRAFV600E mutation was associated with poor outcomes.
– Neil Majithia, MD
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far

User avatar
CRguy
Posts: 9928
Joined: Sun Feb 10, 2008 6:00 pm

3 vs 6 Months of Adjuvant FOLFOX or CAPOX for High-Risk Stage II and Stage III Colon Cancer

Postby CRguy » Fri Jul 12, 2019 4:03 pm

3 vs 6 Months of Adjuvant FOLFOX or CAPOX for High-Risk Stage II and Stage III Colon Cancer

https://www.practiceupdate.com/journals ... rt-insight

TAKE-HOME MESSAGE
• This randomized trial was designed to compare 3 versus 6 months of oxaliplatin/ fluoropyrimidine–based adjuvant chemotherapy for high-risk stage II and stage III colon cancer. The overall 3-year disease-free survival (DFS) rate was 77.2% in the 3-month group versus 77.9% in the 6-month group. The 3-year DFS was dependent on the regimen used, consistent with data from the global IDEA project.
• The DFS appears to be associated with the adjuvant regimen chosen, and the regimen and duration should be personalized.
– Neil Majithia, MD
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: No registered users and 33 guests